In: Non-small cell lung cancer

SYS6010

CSPC

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
15 active
15 in total
Targets
 

What this is

How it works
EGFR-targeted antibody-drug conjugate
How it’s given
“SYS6010 is Lyophilized powder for injection as an EGFR-ADC. SYS6010 will be administered via intravenous infusion, Q3W, with 21 days as one treatment cycle, at a dose of 4.5 mg/kg.”In the company’s words, NCT07633873 on ClinicalTrials.gov
Tested for
Non-Small Cell Lung Cancer (4 trials), Head and Neck Squamous Cell Carcinoma (2 trials), Esophageal Squamous Cell Carcinoma (2 trials), Advanced Solid Tumors (2 trials), EGFR-mutated Locally Advanced or Metastatic NSCLC, NSCLC, Locally Advanced/Metastatic/Recurrent ESCC, Recurrent or Metastatic Breast Cancer and 2 more
Main trialPhase 3
“To evaluate the efficacy and safety of SYS6010 versus platinum-based chemotherapy in participants with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC)”In the company’s words, NCT06927986 on ClinicalTrials.gov

Coming up12

Changes3

Last 90 days

Trials15

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 30 Jul 2026 Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC(SYNSTAR01)
Phase 3Not yet recruiting 12 Dec 2026 A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC
Phase 3Not yet recruiting 30 Sep 2027 SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC(SYNSTAR 04)
Phase 3Not yet recruiting 30 Dec 2027 SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ
Phase 3Not yet recruiting 15 Sep 2028 SYS6010 vs Investigator's Choice of Monotherapy in Patients With Recurrent or Metastatic HNSCC
Phase 3Not yet recruiting 31 Dec 2028 SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma
Phase 3Not yet recruiting 1 Apr 2029 A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer
Phase 3Recruiting 30 Sep 2029 A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)
Phase 3Recruiting 1 Oct 2029 A Study of SYS6010 Combined With Enlonstobart in Patients With Previously Systemic Treatment-Naive R/M Nasopharyngeal Carcinoma
Phase 3Not yet recruiting 30 Dec 2029 A Randomized, Controlled, Double-Blind, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of Enlonstobart, With or Without SYS6010 as Adjuvant Therapy, in Participants With Pathologically Residual Esophageal Squamous Cell Carcinoma Following Complete Surgical Resection
Phase 2/3Not yet recruiting 30 Dec 2029 A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.
Phase 2Not yet recruiting 30 Nov 2026 A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer
Phase 2Recruiting 30 Jun 2028 SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma
Phase 1/2Not yet recruiting 15 Jun 2027 Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors
Phase 1/2Recruiting 30 Oct 2027 A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 16 Nov 2026 · EU trials register (CTIS) updated 16 Nov 2026 · openFDA updated 13 Nov 2026

Follow SYS6010

Following is part of Solo: you see every change to SYS6010 the day it happens.

Solo

$49a month

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in